The Effectiveness of the Harm Reduction Group Therapy Based on Bandura's Self-Efficacy Theory on Risky Behaviors of Drug-Dependent Sex Worker Women

Document Type : Original Article(s)


1 Kerman Health Center, Kerman University of Medical Sciences, Kerman, Iran

2 Community Mental Health Center, Kerman University of Medical Sciences, Kerman, Iran

3 Associate Professor, Department of Psychiatry, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

4 Health Deputy, Kerman University of Medical Sciences, Kerman, Iran

5 PhD Candidate, Neuroscience Research Center, Kerman University of Medical Sciences, Kerman, Iran

6 Forensic Psychiatry, Forensic Medicine, Kerman, Iran

7 General Practitioner, Deputy for Health, Kerman University of Medical Sciences, Kerman, Iran


Background: The aim of this study was to investigate the effectiveness of the harm reduction group therapy based on Bandura's self-efficacy theory on risky behaviors of sex workers in Kerman, Iran.Methods: A quasi-experimental two-group design (a random selection with pre-test and post-test) was used. A risky behaviors questionnaire was used to collect. The sample was selected among sex workers referring to drop-in centers in Kerman. Subjects were allocated to two groups and were randomly classified into two experimental and control groups. The sample group consisted of 56 subjects. The experimental design was carried out during 12 sessions, and the post-test was performed one month and two weeks after the completion of the sessions. The results were analyzed statistically.Findings: By reducing harm based on Bandura's self-efficacy theory, the risky behaviors of the experimental group, including injection behavior, sexual behavior, violence, and damage to the skin, were significantly reduced in the pre-test compared to the post-test (P < 0.010).Conclusion: The harm reduction group therapy based on Bandura's self-efficacy theory can reduce the risky behaviors of sex workers.


  1. Katz MH, Schwarcz SK, Kellogg TA, Klausner JD, Dilley JW, Gibson S, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health 2002; 92(3): 388-94.
  2. Colfax G, Coates TJ, Husnik MJ, Huang Y, Buchbinder S, Koblin B, et al. Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of san francisco men who have sex with men. J Urban Health 2005; 82(1 Suppl 1): i62-i70.
  3. Stall R, Paul JP, Greenwood G, Pollack LM, Bein E, Crosby GM, et al. Alcohol use, drug use and alcohol-related problems among men who have sex with men: The Urban Men's Health Study. Addiction 2001; 96(11): 1589-601.
  4. Woody GE, Donnell D, Seage GR, Metzger D, Marmor M, Koblin BA, et al. Non-injection substance use correlates with risky sex among men having sex with men: Data from HIVNET. Drug Alcohol Depend 1999; 53(3): 197-205.
  5. Evans JL, Hahn JA, Page-Shafer K, Lum PJ, Stein ES, Davidson PJ, et al. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health 2003; 80(1): 137-46.
  6. Tempalski B, Lieb S, Cleland CM, Cooper H, Brady JE, Friedman SR. HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992-2002. J Urban Health 2009; 86(1): 132-54.
  7. Epperson MW, Khan MR, El-Bassel N, Wu E, Gilbert L. A longitudinal study of incarceration and HIV risk among methadone maintained men and their primary female partners. AIDS Behav 2011; 15(2): 347-55.
  8. Miller M, Neaigus A. Networks, resources and risk among women who use drugs. Soc Sci Med 2001; 52(6): 967-78.
  9. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, et al. Hepatitis C virus seroconversion among young injection drug users: Relationships and risks. J Infect Dis 2002; 186(11): 1558-64.
  10. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86(5): 655-61.
  11. World Health Organization. Global report: UNAIDS Report on the global AIDS epidemic . Geneva, Switzerland: WHO; 2012.
  12. World Health Organization. Global report: UNAIDS Report on the global aids epidemic 2010. Geneva, Switzerland: WHO; 2010.
  13. Celentano DD, Cohn S, Davis RO, Vlahov D. Self-efficacy estimates for drug use practices predict risk reduction among injection drug users. J Urban Health 2002; 79(2): 245-56.
  14. Cox J, De P, Morissette C, Tremblay C, Stephenson R, Allard R, et al. Low perceived benefits and self-efficacy are associated with hepatitis C virus (HCV) infection-related risk among injection drug users. Soc Sci Med 2008; 66(2): 211-20.
  15. Sterk CE, Klein H, Elifson KW. Perceived condom use self-efficacy among at-risk women. AIDS Behav 2003; 7(2): 175-82.
  16. Bandura A. Social cognitive theory: An agentic perspective. Annu Rev Psychol 2001; 52: 1-26.
  17. Pulerwitz J, Amaro H, De Jong W, Gortmaker SL, Rudd R. Relationship power, condom use and HIV risk among women in the USA. AIDS Care 2002; 14(6): 789-800.
  18. Fisher JD, Fisher WA. Changing AIDS-risk behavior. Psychol Bull 1992; 111(3): 455-74.
  19. Bandura A. Perceived self-efficacy in the exercise of control over AIDS infection. Eval Program Plann 1990; 13(1): 9-17.
  20. Kadden RM, Litt MD. The role of self-efficacy in the treatment of substance use disorders. Addict Behav 2011; 36(12): 1120-6.
  21. Farmer MA, Meston CM. Predictors of condom use self-efficacy in an ethnically diverse university sample. Arch Sex Behav 2006; 35(3): 313-26.
  22. Baele J, Dusseldorp E, Maes S. Condom use self-efficacy: Effect on intended and actual condom use in adolescents. J Adolesc Health 2001; 28(5): 421-31.
  23. Brafford LJ, Beck KH. Development and validation of a condom self-efficacy scale for college students. J Am Coll Health 1991; 39(5): 219-25.
  24. Fry C, Rumbold G, Lintzeris N. The blood borne virus transmission risk assessment questionnaire (BBVTRAQ): Administration and procedures manual. Melbourne, Australia: Turning Point Alcohol and Drug Centre; 1998.
  25. Fry CL, Lintzeris N. Psychometric properties of the Blood-Borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ). Addiction 2003; 98(2): 171-8.
  26. Gollub EL, French P, Loundou A, Latka M, Rogers C, Stein Z. A randomized trial of hierarchical counseling in a short, clinic-based intervention to reduce the risk of sexually transmitted diseases in women. AIDS 2000; 14(9): 1249-55.
  27. Waldron HB, Kaminer Y. On the learning curve: The emerging evidence supporting cognitive-behavioral therapies for adolescent substance abuse. Addiction 2004; 99 Suppl 2: 93-105.
  28. Dolan KA, Niven H. A review of HIV prevention among young injecting drug users: A guide for researchers. Harm Reduct J 2005; 2(1): 5.
  29. Ruan Y, Liang S, Zhu J, Li X, Pan SW, Liu Q, et al. Evaluation of harm reduction programs on seroincidence of HIV, hepatitis B and C, and syphilis among intravenous drug users in southwest China. Sex Transm Dis 2013; 40(4): 323-8.
  30. Crepaz N, Marshall KJ, Aupont LW, Jacobs ED, Mizuno Y, Kay LS, et al. The efficacy of HIV/STI behavioral interventions for African American females in the United States: A meta-analysis. Am J Public Health 2009; 99(11): 2069-78.